19.7 C
New York
Saturday, June 29, 2024

Food and Drug Administration advisers are reviewing the Alzheimer's drug Donanemab


FDA advisers are set to review an Alzheimer’s drug found to slow the disease’s progress in patients in the early stages. The big questions are about how the drug should be marketed.



Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

error: Content is protected !!